Pulmonary Arterial Hypertension (PAH) is a rare and progressive disorder characterized by high blood pressure in the arteries of the lungs (pulmonary arteries). This condition causes the arteries to become narrowed or blocked, making it difficult for blood to flow through the lungs, ultimately leading to increased pressure on the heart and reduced oxygen supply to the body. Over time, PAH can cause the heart’s right ventricle to weaken, resulting in heart failure and severe complications if untreated.
Patients are the experts in their condition and advocacy groups provide a platform for patient voices. Working directly with these communities is the key to pushing research forward in an inclusive way.
We’ve committed to having 500,000 conversations in the next three years, to equip ourselves and our Pharma partners with the insights needed to increase predictability.
Read more...
The ever-growing investment in advocacy doesn’t appear to be slowing down, and research is certainly seeing the benefits. Which at the end of the day, means better patient care and more options for patients
Read more...
We’re ready to keep forming links between our Advocacy friends and Pharma partners, so these fruitful relationships continue to evolve beyond the study-to-study view.
Read more...